Botulinum toxin type A injection for management of upper limb spasticity in children with cerebral palsy: A literature review

Yonsei Medical Journal

Volumn 47, Issue 5, 2006, Pages 589-603

  Park, Eun Sook ^a   Rha, Dong Wook ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Botulinum toxin type A; Cerebral palsy; Spasticity; Upper limb

Indexed keywords

BOTULINUM TOXIN A;

AGE; ARM; CEREBRAL PALSY; CHILD; CINAHL; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; FUNCTIONAL ASSESSMENT; HUMAN; INJECTION; MEDLINE; MUSCLE TONE; PRACTICE GUIDELINE; RANGE OF MOTION; REVIEW; SPASTICITY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGE FACTORS; BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INJECTIONS; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; RANGE OF MOTION, ARTICULAR; UPPER EXTREMITY;

EID: 33750697902     PISSN: 05135796     EISSN: 05135796     Source Type: Journal    
DOI: 10.3349/ymj.2006.47.5.589     Document Type: Review

References (45)

1. Gormley ME, Gaebler-Spira D, Delgado MR. Use of botulinum toxin type A in pediatric patients with cerebral palsy: a three-center retrospective chart review. J Child Neurol 2001;16:113-8.
2. Russman BS, Tilton A, Gormley ME Jr. Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle Nerve Suppl 1997;6:S181-93.
3. Corry IS. Use of a motion analysis laboratory in assessing the effects of botulinum toxin in a cerebral palsy. Thesis for doctor of medicine in the faculty of medicine. Belfast (North Ireland): The Queens University; 1995.
4. Cosgrove AP, Graham HK. Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse. Dev Med Child Neurol 1994;36:379-85.
5. Dunne JW, Heye N, Dunne SL. Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry 1995;58:232-5.
6. Lance JW. Pathophysiology of spasticity and clinical experience of baclofen. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Chicago: Year Book Medical Publishers; 1980. p.185-203.
7. Ziv I, Blackburn N, Rang M, Koreska J. Muscle growth in normal and spastic mice. Dev Med Child Neurol 1984;26:94-9.
8. Mohamed KA, Moore AP, Rosenbloom L. Adverse events following repeated injections with botulinum toxin A in children with spasticity. Dev Med Child Neurol 2001;43:791.
9. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001;8 (Suppl 5):21-9.
10. Buttler C. American Academy of Cerebral Palsy and Developmental Medicine methodology for developing evidence tables and reviewing treatment outcomes research. Available from: URL: www.aacpdm.org/resources/ But-guide.pdf.
11. Fehlings D, Rang M, Glazier J, Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr 2000;137:331-7.
12. Friedman A, Diamond M, Johnston MV, Daffner C. Effects of botulinum toxin A on upper limb spasticity in children with cerebral palsy. Am J Phys Med Rehabil 2000;79:53-9; quiz 75-6.
13. Gooch JL, Sandell TV. Botulinum toxin for spasticity and athetosis in children with cerebral palsy. Arch Phys Med Rehabil 1996;77:508-11.
14. Wallen MA, O'Flaherty S J, Waugh MC. Functional outcomes of intramuscular botulinum toxin type A in the upper limbs of children with cerebral palsy: a phase II trial. Arch Phys Med Rehabil 2004;85:192-200.
15. Wong V, Ng A, Sit P. Open-label study of botulinum toxin for upper limb spasticity in cerebral palsy. J Child Neurol 2002;17:138-42.
16. Autti-Ramo I, Larsen A, Taimo A, von Wendt L. Management of the upper limb with botulinum toxin type A in children with spastic type cerebral palsy and acquired brain injury: clinical implications. Eur J Neurol 2001;8 (Suppl 5):136-44.
17. Lowe K, Novak I, Cusick A. Low-dose/high-concentration localized botulinum toxin A improves upper limb movement and function in children with hemiplegic cerebral palsy. Dev Med Child Neurol 2006;48:170-5.
18. Fehlings D, Rang M, Glazier J, Steele C. Botulinum toxin type A injections in the spastic upper extremity of children with hemiplegia: child characteristics that predict a positive outcome. Eur J Neurol 2001;8 (Suppl 5):145-9.
19. Hurvitz EA, Conti GE, Brown SH. Changes in movement characteristics of the spastic upper extremity after botulinum toxin injection. Arch Phys Med Rehabil 2003;84:444-54.
20. Hurvitz EA, Conti GE, Flansburg EL, Brown SH. Motor control testing of upper limb function after botulinum toxin injection: a case study. Arch Phys Med Rebabil 2000;81:1408-15.
21. Yang TF, Fu CP, Kao NT, Chan RC, Chen SJ. Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity. Am J Phys Med Rehabil 2003;82:284-9.
22. Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK. Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol 1997;39: 185-93.
23. Speth LA, Leffers P, Janssen-Potten YJ, Vles JS. Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy. Dev Med Child Neurol 2005;47:468-73.
24. Mall V, Heinen F, Linder M, Philipsen A, Korinthenberg R. Treatment of cerebral palsy with botulinum toxin A: functional benefit and reduction of disability. Three case reports. Pediatr Rehabil 1997;1:235-7.
25. Graham HK, Aoki KR, Autti-Ramo I, Boyd RN, Delgado MR, Gaebler-Spira DJ, et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 2000;11:67-79.
26. Kinnett D. Botulinum toxin A injections in children: technique and dosing issues. Am J Phys Med Rehabil 2004;83:S59-64.
27. Hsu TS, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 2004;140:1351-4.
28. Arens LJ, Leary PM, Goldschmidt RB. Experience with botulinum toxin in the treatment of cerebral palsy. S Afr Med J 1997;87:1001-3.
29. Denislic M, Mch D. Botulinum toxin in the treatment of cerebral palsy. Neuropediatrics 1995;26:249-52.
30. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964;192:540-2.
31. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67:206-7.
32. Lakie M, Walsh EG, Wright GW. Assessment of human hemiplegic spasticity by a resonant frequency method. Clin Biomech 1988;3:173-8.
33. Tardieu G, Shentoub S, Delarue R. Research on a technic for measurement of spasticity. Rev Neurol (Paris) 1954;91:143-4.
34. Norkin CC, White DJ. Measurement of joint motion: A guide to goniometry. 3rd ed. Philadelphia: F.A. Davis Company; 2003.
35. Wall SA, Chait LA, Temlett JA, Perkins B, Hillen G, Becker P. Botulinum A chemodenervation: a new modality in cerebral palsied hands. Br J Plast Surg 1993; 46:703-6.
36. DcMatteo C, Law M, Russell D, Pollock N, Rosenbaum P, Walter S. The reliability and validity of the quality of upper extremity skills test. Pediatric Phys Occup Ther 1993;13:1-18.
37. Randall M, Carlin JB, Chondros P, Reddihough D. Reliability of the Melbourne assessment of unilateral upper limb function. Dev Med Child Neurol 2001;43: 761-7.
38. Boyd RN, Graham HK. Botulinum toxin A in the management of children with cerebral palsy: indications and outcome. Eur J Neurol 1997;4:S15-22.
39. Boyd RN, Hays RM. Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review. Eur J Neurol 2001;8:S1-20.
40. Chin TY, Nattrass GR, Selber P, Graham HK. Accuracy of intramuscular injection of botulinum toxin A in juvenile cerebral palsy: a comparison between manual needle placement and placement guided by electrical stimulation. J Pediatr Orthop 2005;25:286-91.
41. Childers MK. Targeting the neuromuscular junction in skeletal muscles. Am J Phys Med Rehabil 2004;83:S38-44.
42. Berweck S, Schroeder AS, Fietzek UM, Heinen F. Sonography-guided injection of botulinum toxin in children with cerebral palsy. Lancet 2004;363:249-50.
43. Kim HS, Hwang JH, Jeong ST, Lee YT, Lee PK, Suh YL, et al. Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol 2003;45:200-6.
44. Shaari CM, Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve 1993;16:964-9.
45. Francisco GE. Botulinum toxin: dosing and dilution. Am J Phys Med Rehabil 2004;83:S30-7.